ClinicalTrials.gg
Active, not recruitingNCT05760989TRISCEND JAPANUpdated Oct 27, 2026Results posted

TRISCEND JAPAN Study

An interventional study of Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System in Tricuspid Valve Regurgitation, Heart Valve Diseases and Cardiovascular Diseases, sponsored by Edwards Lifesciences. Active, not recruiting at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences — 3 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Edwards Lifesciences.

Started
2023
the only one that year
No phase
9 of 14
none open now
Registered
11th of 14
by date

Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, this one is the only one that started in 2023, is one of 9 with no phase, and was the 11th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

3 of the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

A prospective, open, non-randomized, multicenter, clinical trial to evaluate the safety and effectiveness of the Edwards EWJ-202 transcatheter tricuspid valve replacement system in the treatment of patients with at least severe tricuspid regurgitation despite medical therapy. Subjects will be followed at discharge, 30 days, 6 months and annually through 5 years.

03

Conditions studied

  • Tricuspid Valve Regurgitation
  • Heart Valve Diseases
  • Cardiovascular Diseases

Keywords

  • Transcatheter
  • Tricuspid Disease
  • Valve Replacement
  • Tricuspid Valve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic tricuspid regurgitation (TR) despite medical therapy
  • TR graded as severe or greater
  • Appropriate for transcatheter tricuspid valve replacement per the local heart team

Exclusion criteria

Exclusion Criteria:

  • Tricuspid valve anatomic
  • Need for emergent or urgent surgery or any planned cardiac surgery within the next 12 months
  • Hemodynamic instability
  • heart failure requiring advanced intervention
  • Currently participating in another study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Treatment with the Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System

    Device: Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System

Interventions

  • DeviceEdwards EWJ-202 Transcatheter Tricuspid Valve Replacement System

    Replacement of the native tricuspid valve through a transcatheter approach

06

What researchers measure

Primary outcomes

  1. All-Cause Mortality

    Co-primary Endpoint: All-cause mortality through 1 year, estimated using the Kaplan-Meier method.

    Time frame: 1 year

  2. Heart Failure Hospitalization

    Co-primary Endpoint: Heart failure hospitalization through 1 year, estimated using the Kaplan-Meier method.

    Time frame: 1 Year

Secondary outcomes

  1. Composite Major Adverse Event (MAE) Rate Through 30 Days

    Composite MAE rate through 30 days, including cardiovascular mortality, myocardial infarction, stroke, new need for renal therapy, severe bleeding, non-elective tricuspid valve re-intervention (percutaneous or surgical), major access site and vascular complications, major cardiac structural complications due to access-related issues, device-related pulmonary embolism, arrhythmia and conduction disorder requiring permanent pacing.

    Time frame: 30 Days

07

Results

Posted Oct 27, 2026
Limitations and caveats
\[Not Specified\]

Participant flow

\[Not Specified\]

30-Day Follow-up (Day 37)
Participant flow — 30-Day Follow-up (Day 37)
MilestoneEdwards EVOQUE Tricuspid Valve Replacement System
Started53
Completed53
Not completed0
1-Year Follow-up (Day 410)
Participant flow — 1-Year Follow-up (Day 410)
MilestoneEdwards EVOQUE Tricuspid Valve Replacement System
Started53
Completed48
Not completed5
Withdrew: Withdrawal by subject1
Withdrew: Death4

Outcome measures

PrimaryAll-Cause Mortality

Co-primary Endpoint: All-cause mortality through 1 year, estimated using the Kaplan-Meier method.

Time frame:
1 year
Reported as:
Number · Percentage of Participants
All-Cause Mortality
Percentage of ParticipantsEdwards EVOQUE Tricuspid Valve Replacement System
All-Cause Mortality7.7 (3.0 to 19.2)
PrimaryHeart Failure Hospitalization

Co-primary Endpoint: Heart failure hospitalization through 1 year, estimated using the Kaplan-Meier method.

Time frame:
1 Year
Reported as:
Number · Percentage of Participants
Heart Failure Hospitalization
Percentage of ParticipantsEdwards EVOQUE Tricuspid Valve Replacement System
Heart Failure Hospitalization7.6 (2.9 to 19.1)
SecondaryComposite Major Adverse Event (MAE) Rate Through 30 Days

Composite MAE rate through 30 days, including cardiovascular mortality, myocardial infarction, stroke, new need for renal therapy, severe bleeding, non-elective tricuspid valve re-intervention (percutaneous or surgical), major access site and vascular complications, major cardiac structural complications due to access-related issues, device-related pulmonary embolism, arrhythmia and conduction disorder requiring permanent pacing.

Time frame:
30 Days
Reported as:
Count of participants · Participants
Composite Major Adverse Event (MAE) Rate Through 30 Days
ParticipantsEdwards EVOQUE Tricuspid Valve Replacement System
Composite Major Adverse Event (MAE) Rate Through 30 Days12

Adverse events

Collected over All-cause mortality was assessed through the 1-year follow-up period (Day 410). Serious adverse events and other (not including serious) adverse events were assessed through Day 365.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Edwards EVOQUE Tricuspid Valve Replacement System4/53 (7.5%)29/53 (54.7%)18/53 (34%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventEdwards EVOQUE Tricuspid Valve Replacement System
Atrioventricular block completeCardiac disorders7/53
Cardiac failureCardiac disorders6/53
Prosthetic cardiac valve thrombosisGeneral disorders3/53
PyrexiaGeneral disorders3/53
COVID-19Infections and infestations3/53
AnaemiaBlood and lymphatic system disorders2/53
Atrial fibrillationCardiac disorders2/53
Lower gastrointestinal haemorrhageGastrointestinal disorders2/53
Cardiac failure chronicCardiac disorders1/53
Mitral valve incompetenceCardiac disorders1/53
Most frequent other events
Most frequent other events
EventEdwards EVOQUE Tricuspid Valve Replacement System
Bundle branch block rightCardiac disorders6/53
Cardiac failureCardiac disorders4/53
ContusionInjury, poisoning and procedural complications4/53
AnaemiaBlood and lymphatic system disorders3/53
Compression fractureInjury, poisoning and procedural complications3/53
Head injuryInjury, poisoning and procedural complications3/53

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Edwards EVOQUE Tricuspid Valve Replacement System
Mean82.6 ± 5.11
Sex: Female, Male
Sex: Female, Male(Participants)Edwards EVOQUE Tricuspid Valve Replacement System
Female26
Male27
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Edwards EVOQUE Tricuspid Valve Replacement System
Cardiac Valve Disease (stenosis or regurgitation, excluding tricuspid)
Cardiac Valve Disease (stenosis or regurgitation, excluding tricuspid)(Participants)Edwards EVOQUE Tricuspid Valve Replacement System
Aortic2
Mitral4
Pulmonic0
08

Study locations

8 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Aug 2025, 30 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's 30 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Aug 2025, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 9, 2023
StartActual
Feb 6, 2023
Primary completionActual
Aug 18, 2025was Sep 2025
CompletionEst.
Sep 30, 2029
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Japan)
  • Sendai Kousei Hospital · Sendai, Japan
  • Osaka Keisatsu Hospital · Osaka, Japan
Show 2 removed
  • Sendai Kousei Hospital · Sendai-shi, Japan
  • Osaka Keisatsu Hospital · Osaka-shi, Japan
Oct 27, 2026
Primary completion
Sep 30, 2025→Aug 18, 2025 (actual)
Oct 27, 2026
Enrollment
45 (estimated)→53 (actual)
Oct 27, 2026
Primary outcomes
1 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameHeart Failure Hospitalization1 year → 1 Year
  • DescriptionAll-Cause Mortality: how it is measured was reworded
  • DescriptionHeart Failure Hospitalization: how it is measured was reworded
Oct 27, 2026
Documents
Secondary outcomes
1 added, 8 removed
What changed in the outcomes
  • AddedComposite Major Adverse Event (MAE) Rate Through 30 DaysTime frame: 30 Days
  • RemovedRates of various adverse eventsTime frame: 30 days, 6 months, 12 months, annual for five years
  • RemovedRate of Major Adverse Events (MAEs)Time frame: 30 days
  • RemovedReduction in TR gradeTime frame: 30 days, 6 months, 12 months, annual for five years
  • RemovedNew York Heart Association (NYHA) Functional ClassTime frame: 30 days, 6 months, 12 months, annual for five years
  • RemovedHealth Status as measured by the SF-36 QuestionnaireTime frame: 30 days, 6 months, 12 months, annual for five years
  • RemovedHealth Status as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)Time frame: 30 days, 6 months, 12 months, annual for five years
  • RemovedHealth Status as measured by the EQ-5D-5L QuestionnaireTime frame: 30 days, 6 months, 12 months, annual for five years
  • RemovedSix-minute walk testTime frame: 30 days, 6 months, 12 months, annual for five years
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (2 Japan)
    • Sendai Kousei Hospital · Sendai, Japan
    • Osaka Keisatsu Hospital · Osaka, Japan
    Show 2 removed
    • Sendai Kousei Hospital · Sendai-shi, Japan
    • Osaka Keisatsu Hospital · Osaka-shi, Japan
    Primary completion Sep 30, 2025→Aug 18, 2025 (now actual)
    Enrollment 45 (estimated)→53 (actual)
    Primary outcomes 1 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameHeart Failure Hospitalization1 year → 1 Year
    • DescriptionAll-Cause Mortality: how it is measured was reworded
    • DescriptionHeart Failure Hospitalization: how it is measured was reworded
    Secondary outcomes 1 added, 8 removed
    What changed in the outcomes
    • AddedComposite Major Adverse Event (MAE) Rate Through 30 DaysTime frame: 30 Days
    • RemovedRates of various adverse eventsTime frame: 30 days, 6 months, 12 months, annual for five years
    • RemovedRate of Major Adverse Events (MAEs)Time frame: 30 days
    • RemovedReduction in TR gradeTime frame: 30 days, 6 months, 12 months, annual for five years
    • RemovedNew York Heart Association (NYHA) Functional ClassTime frame: 30 days, 6 months, 12 months, annual for five years
    • RemovedHealth Status as measured by the SF-36 QuestionnaireTime frame: 30 days, 6 months, 12 months, annual for five years
    • RemovedHealth Status as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)Time frame: 30 days, 6 months, 12 months, annual for five years
    • RemovedHealth Status as measured by the EQ-5D-5L QuestionnaireTime frame: 30 days, 6 months, 12 months, annual for five years
    • RemovedSix-minute walk testTime frame: 30 days, 6 months, 12 months, annual for five years
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05760989
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Feb 6, 2023
Primary completion
Aug 18, 2025
Completion
Sep 30, 2029 (estimated)
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Yoshihiro Morino, MD
study chair · Iwate Medical University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion